Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
will be reporting earnings this Tuesday after market hours. Here’s what you need to know.
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly enhances the precision of drug development from initial discovery to commercial manufacturing. This fundamental shift is giving rise to the "TechBio" era, where AI is no longer merely a supporting tool but the [...]
Shares of life sciences company Bio-Techne (NASDAQ:TECH)
jumped 2.8% in the afternoon session after Baird adjusted its price target on the company, signaling a more positive outlook. The investment firm raised its price target on Bio-Techne to $62 from $53. The stock's rise also occurred as the broader market showed strength. Stocks rose after solid earnings reports from major tech companies like Apple and Amazon beat expectations, which seemed to spark a rally in the sector. Bio-Techne's move followed a recent period of volatility, which included a sharp surge of over 18% in the preceding month.
Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on strong obesity drug momentum.
Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC)
jumped 3.2% in the afternoon session after it reported strong third-quarter financial results that surpassed expectations and raised its full-year guidance. The company's revenue for the quarter reached $192.9 million, a 30.7% increase from the same period last year, beating analysts' projections by approximately $8.5 million. Furthermore, iRhythm significantly narrowed its losses, reporting an adjusted loss per share of $0.06, a substantial improvement from a loss of $1.26 per share in the same quarter of the previous year and well ahead of analysts' estimates. In light of the strong performance, the company increased its full-year 2025 revenue forecast to a midpoint of $737.5 million.
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of excipient development. These "inactive" ingredients, which constitute the bulk of most drug formulations, are now at the forefront of an AI-driven innovation wave. By leveraging advanced [...]
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to market. Driven by advanced data integration and sophisticated analytics, AI is dramatically accelerating timelines, reducing costs, and significantly improving success rates across the entire drug development pipeline. This paradigm [...]
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late 2025, an established force, fundamentally reshaping drug development and operational workflows. This shift is not merely incremental but a comprehensive revolution, accelerating Research & [...]
Wall Street slipped on Thursday as disappointing results from Meta and cautious tones from the Fed weighed on sentiment. But after the closing bell, Apple’s record-breaking numbers helped restore a bit of optimism.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have caused the industry to lag recently -
over the past six months, the collective 9.8% gain for healthcare stocks has fallen short of the S&P 500’s 22.6% rise.
